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ABSTRACT
The growing use of psychoactive substances in everyday life, the increasing experimentation among
users and the potential of poly drug use for non-medical, lifestyle or enhancement purposes presents
an evolving policy challenge. The paper aims to build on previous research to gain a more in-depth
qualitative understanding of the imaginaries around pharmaceutical cognitive enhancement (PCE). It
focuses in particular on how the so-called pharmaceutical cognitive enhancing drugs (PCEDs) might be
used and the social acceptability of these uses across multiple social contexts and groups. Data come
from 23 focus groups (99 participants), representing a wide range of social groups, recruited in the UK.
We discuss four distinct ‘enhancement practices’ where PCE use was conceptualised as a way to (1)
become the best version of oneself; (2) gain a competitive edge over others; (3) for personal achieve-
ment or well-being; and (4) promote personal/public safety. The findings problematise the term
‘enhancement’ by showing the different ways in which the use of pharmaceutical ‘enhancement’ drugs
can be imagined and understood. We argue for the value of policy responses that acknowledge and
respond to a wider range of enhancement practices including those of prospective user groups.
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Pharmaceutical enhancement drugs (PCEDs)
The term ‘cognition enhancing drug’ can refer to a wide
range of substances, from prescription medications to caf-
feine to illegal drugs. The majority of drugs we have come to
think of as potential ‘cognitive enhancers’ are readily avail-
able across the world as licenced medicines, their use con-
trolled by prescription for particular medical indications. The
term PCED provides a narrower focus and is usually used to
refer to these prescription medications.
Typically, studies have focussed on a small number of pre-
scription drugs such as methylphenidate (e.g. Ritalin,
Concerta), modafinil and amphetamine type drugs that have
the potential to be used outside of their licenced indications
to augment cognitive functions (e.g. Schelle et al., 2015).
Methylphenidate is widely prescribed for people diag-
nosed with attention deficit/hyperactivity disorder and has
been studied in healthy populations as a means of improving
cognitive performance (Jansen, 2017). Modafinil is a wakeful-
ness promoting drug that is prescribed to promote alertness
in those with sleep disorders involving excessive sleepiness
(such as narcolepsy) and can be prescribed off-label to peo-
ple with Chronic Fatigue Syndrome, cancer and Parkinson’s
disease. It has been shown to provide a variety of other
moderate cognitive benefits in those without illness, includ-
ing improved concentration, memory and motivation (Muller
et al, 2013). Other less frequently studied drugs include
Atomoxetine – a drug that is licenced in the UK for the man-
agement of ADHD to improve alertness, attention and focus,
but has significant cardiotoxic effects, Donepezil which is pre-
scribed to patients with Alzheimer’s disease to improve atten-
tion, memory and social interaction (Dodou & Nazar, 2013),
rivastigmine and beta blockers (Schelle et al., 2015).
However, the number of potential PCEDs could far exceed
this. For instance, in late 2014, the UK Medicines and
Healthcare products Regulatory Agency (MHRA) issued a press
release announcing the seizure of over 20,000 units of 13 differ-
ent types of cognition enhancing drugs, including unlicensed
substances that had not been tested in humans. The press
release claims that this event in and of itself illustrates the
‘burgeoning demand and variety of new active substances
entering the marketplace’ and highlights concerns around ‘the
increasing experimentation amongst users’ (MHRA, 2014).
The availability of PCEDs has led to much debate and
speculation that there will be a significant lifestyle or recre-
ational market for these substances in all areas of social life.
As is alluded to in the MHRA statement above, the potential
use of psychoactive substances for enhancement purposes,
the increasing experimentation among users and the
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potential of poly drug use for enhancement purposes present
evolving policy challenges. This in turn is part and parcel of
wider debates on the problems and promises of human
enhancement today. For example, some are of a more
‘precautionary’ persuasion while others stress more
‘proactionary’ principles and imperatives which embrace risk
taking. Then there are more collective and democratic issues
of social justice and social welfare which these debates raise
(see, for example, Lipinska & Fuller, 2014).
Enhancement imaginaries in UK research, media
and policy
However, as is often the case for new and emerging uses of
technology, in this case, pharmaceuticals as biomedical tech-
nology, little is known about the prospective and/or actual
user populations. In such cases, societal and policy responses
can often come to rest on imaginaries of drug use, imagin-
ings of users and assumptions about their desires, motiva-
tions and experiences (Outram, 2011). Social imaginaries can
be defined as a collective set of beliefs, shared understand-
ings or expectations that exist amongst a (historically or geo-
graphically) distinct group of people (Taylor, 2004). Steger
(2014: 25) argues that social imaginaries are ‘macro-mappings
of social and political space through which we perceive,
judge, and act in the world’ and thus can set the parameters
within which we understand ourselves, our actions and our
collective sense of their legitimacy. Imaginaries are not fixed,
but flexible and open to new configurations.
In relation to new and emerging technologies, such as
PCEDs, the ways in which prospective users, their motivations
for use and effects of drug use are imagined is often through
bioethical or neuroethical discourses and debates (De Vries,
2007; Greely et al., 2008; Harris, 2011) where the deployment
of such ethical expertise becomes the mechanism through
which public concerns are both raised and adjudicated (Rose,
2009; Martin, Pickersgill, Coveney, & Williams, 2011).
Together, these stories, images and understandings craft a
particular version of cognitive enhancement and enhance-
ment drug use that infiltrates popular consciousness and
recirculates in other arenas such as research agendas, policy
and regulatory responses, and media discourses.
Dominant ‘social imaginaries’ (Taylor, 2004) of PCED use
depict users as knowledge workers (including professionals
and students) and those in safety critical occupations – such
as military personnel, fire-fighters and medical professionals
(Coveney, 2011). Their motivations for use are configured in
terms of the ‘improvement’ or ‘enhancement’ of cognitive
capabilities in a way that benefits workplace performance.
We can see this clearly in media coverage of cognitive
enhancing drugs, with for example, claims that we are in the
midst of a so-called ‘smart drugs epidemic’ where ‘up to 1 in
12 people’ are now said to take smart drugs, due to pressure
to perform at work and at University (The Telegraph, 2018).
The drugs, we are told, are being used by those striving for
higher levels of performance, to help them work longer
hours, to excel in the workplace, to earn more money and
get higher grades (The Tab, 2014; BBC News 2018).
In relation to drug policy, social imaginaries can be viewed
as organising principles around which particular policy
responses are structured. Imagined users are embedded
within these sociotechnical imaginaries, and these conceptu-
alisations can be used to define and support particular policy
regimens (Cherry, Hopfe, MacGillivray, & Pidgeon, 2017). For
example, we can see this in relation to the way in which
modafinil is regulated. In 2010, the European Medicines
Agency advised that the availability of modafinil should be
more restricted and only prescribed for narcolepsy, citing its
potential to be abused by students as one reason for these
tighter controls (EMA, 2010). These regulatory changes came
about despite modafinil being considered a relatively safe
drug and limited empirical evidence that students were actu-
ally using modafinil as a study to any great extent at
that time.
It is also these groups who have dominated most research
efforts to understand PCED use. A significant proportion of
research in this field has used surveys to focus on the moti-
vations and practices of students or young adults, to the rela-
tive exclusion of other social groups. Often these surveys
provide pre-defined options for participants to select regard-
ing their motivations for PCED use, preconfiguring the
answers that they are likely to provide and arguably repro-
ducing dominant enhancement imaginaries (e.g. PCEDs are/
will be ab/used by students in their attempts to get better
grades) that circulate in academic literature, policy discourse
and popular media.
There are only a small number of qualitative studies focus-
sing on perceptions and practices of cognitive enhancement
across different social groups as understood and defined by
different types of user – be that actual, prospective or non-
users (e.g. Coveney, 2011; LeClair, Kelly, Pawson, Wells, &
Parsons, 2015; Petersen, Nørgaard, & Traulsen, 2015; Vrecko,
2015). Recent work in this area acknowledges the increasing
centrality of pharmaceuticals in everyday self-management
practices (Lopes, Clamote, Raposo, Pegado, & Rodrigues,
2015) showing how PCEDs are often used strategically and
instrumentally, by specific user groups whilst being rejected
by others (Sattler, Mehlkop, Graeff, & Sauer, 2014).
Collectively these qualitative studies reveal that the ways in
which such technologies come to be positioned, accepted,
used or rejected in daily life can be very different from the
ways in which these same technologies are imagined and
discussed in bioethical and biomedical discourses (Pickersgill
& Hogle, 2015). This research has begun to unravel the
‘pharmaceutical regimens’ (Williams, Martin, & Gabe, 2011)
cognitive enhancing drugs are part of; the social context
within which they are developed, regulated and accessed
and the purpose and motivations for their use.
Presently, contemporary UK drug policy is focussed on
strategies to restrict the supply of drugs and limit associated
criminal activity (HM Government, 2017). There is very little
drug policy at the national level specifically aimed at the use
of PCEDs. While it is not illegal to possess these substances,
sale or supply of a prescription only or unlicensed medicine
is a criminal offence in the UK (MHRA, 2014). At the local
level, PCED use remains a largely unregulated practice. Even
in Universities in the UK, where much of the debate on the
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so-called ‘smart’ drugs has tended to focus, information and
policies on PCEDs tends, with few exceptions, to be some-
what limited. If present, information is provided together
with advice on other drugs, and out of step with these wider
debates, including indeed a recent NUS report on these very
matters which calls for a less punitive and more proportion-
ate approach to these issues given their complexities
(National Union of Students, 2018).
As ‘enhancement’ drugs continue to be developed and
their use allegedly proliferates both within the clinical
encounter and beyond, important questions are raised
around drug policy, including what appropriate policy
responses should be at national and local levels, and the
extent to which drug policies should attempt to control, or
even promote the use of PCEDs in particular scenarios
(Greely et al., 2008; Sugden et al., 2012).
In his recent paper, Erler (2017) focuses his attention on
the utility of upholding a therapy-enhancement distinction
(TED) as a guide to public policy. He argues that while there
may be some use in maintaining a TED, it cannot perform
the role expected of it; that is to say what is worthy, accept-
able or justifiable in terms of resource allocation. The TED
assumes that therapy is for medical need and can be justi-
fied, morally and financially, whereas the goal of enhance-
ment is more frivolous, and based on want or preference
rather than need. The assumption being that a pharmaceut-
ical used as an enhancement is not useful or does not yield
benefits for society more widely.
However, in academic circles at least, the blurredness of
the boundaries between what we perceive as being a
necessary medical treatment (or therapy) or an enhance-
ment, and where we draw the lines between health and ill-
ness and dis/ability, are well recognised, including their
socially constructed, historically shifting and contextually
dependent nature (Conrad, 2007). This prompts a need for
more scholarly engagement with issues around enhance-
ment than there has been to date. How one defines
‘enhancement’, what is included or excluded here, what
enhancement involves and the gains as well as losses
entailed, for both individuals and society, are pertinent
sociological questions.
Our aim in this paper is to build on previous research to
gain a more in-depth understanding of how ‘enhancement
imaginaries’ – defined as collective sets of beliefs, shared
understandings and expectations about enhancement
(Steger, 2012; Taylor, 2004) – that circulate in policy, research,
public discourse and the media, are drawn on, reproduced,
developed and/or dismissed by various publics in the ways
they make sense of cognitive enhancement and evaluate the
acceptability of PCED use across multiple contexts and
groups. We end by offering some reflections on future pol-
icy responses.
Materials and methods
Data were collected as part of a wider project exploring
medicated sleep and wakefulness in Britain (full details
redacted). We held 23 focus groups (99 participants) with a
variety of stakeholders who might be expected to have dif-
fering views on the use of modafinil (see Table 1) based on
their age, occupational role and health status. Thirteen of the
participants had experience of using modafinil, methylphen-
idate, amphetamine or other stimulants. All disclosed use
was in the context of treating diagnosed medical conditions.
None of our participants disclosed experience of non-medical
or recreational use of stimulants. Focus groups were held
between 2011 and 2013.
Participants were aged 18–85þ years old with approxi-
mately half of the sample 45 years of age or over. Around 60
per cent of participants were female and around 90 per cent
identified as of white British or Irish ethnicity. Just over half
the sample had, or had previously had before retirement, a
higher managerial or professional job (more information
about sampling and recruitment can be found in Gabe,
Coveney, & Williams, 2016).
Focus groups were used as the means of data collection
in order to explore people’s views about, and experiences of
pharmaceutical use across different medical and non-medical
contexts. This included discussion of different medications
that induce sleep (e.g. hypnotics) and medications that can
promote wakefulness or improve alertness (e.g. stimulants).
The focus group discussion was facilitated by a series of sim-
ple vignettes depicting different types of drug use that might
be considered to blur the therapy/enhancement boundary
(Table 2). Within this, participants were introduced to the
drug modafinil and asked to discuss some of its prospective
uses. Discussions were widened to include other potentially
enhancing prescription medications, over the counter medi-
cations and recreational drugs where the participants had
knowledge or experience of these substances.
Focus groups can be distinguished from one-to-one inter-
views as during a focus group participants are encouraged to
engage with one another and this interaction between par-
ticipants becomes a focus of analysis (Kitzinger, 1994). Using
focus groups as a research tool and eliciting conversations
about PCEDs enabled us to: explore how people imagined
and evaluated PCE and to assess how ideas are formed and
decisions are made regarding the ‘appropriate’ role of these
pharmaceuticals across different contexts. This methodology
not only generates data about what people think about a
certain issue but also draws out the moral dimensions of
how they think about it and why they think as they do.
Focus groups were audio recorded and transcribed.
Analysis of the transcripts was facilitated using the qualitative
data analysis software package NVivo 10 (QSR International,
Brisbane, UK). We took an inductive and interpretative
approach to data analysis which involved reading and re-
reading the transcripts, developing a coding frame based on
major topics and issues and grouping data extracts together
into codes, and connecting congruent codes together to gen-
erate themes. Codes and themes relating to major issues
were discussed between the authors for purposes of reliabil-
ity and validity.
Theoretically our analysis draws on the social science
notion of social imaginaries, as already discussed above, with
particular reference to ‘enhancement imaginaries’ as one spe-
cific type of social imaginary. We will show how the idea of
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PCE and the availability of PCEDs have given rise to a num-
ber of ‘enhancement imaginaries’ in the public domain that
align and/or differ in various ways to the dominant enhance-
ment imaginaries that circulate in contemporary academic,
policy and media discourses.
Results
Through our analysis of the focus group data we generated
key themes corresponding to four different ‘enhancement
imaginaries’, primarily demarcated by the ways in which the
goal of ‘enhancement’ was conceptualised, PCEDs were con-
figured, and the users imagined. These related to enhance-
ment (i) to perform at ones best, (ii) gain a competitive edge
over others, (iii) for personal achievement or well-being, and
(iv) to promote safety of self and others. It is to these key
themes that we now turn.
Pharmaceutical ‘fixes’ to perform at ones best
Within this enhancement imaginary PCEDs were typically
considered to be pharmaceutical ‘fixes’, with the use
Table 1. Focus group demographic characteristics.






1 mixed (White & Asian)
Higher Managerial & Professionals
Ambulance Service Staff
3 groups (ASFG1 -3)
9 5M
4F







Higher Managerial & Professionals
Narcolepsy Patients










1 Higher Managerial & Professionals
Parents of Young Children




1 Asian or AB (Pakistani)
1 White (other)
6 Higher Managerial & Professionals
3 Intermediate
1 Technical & Craft
Primary Care Patients
3 groups (PCFG1 -3)
12 6F
6M
45 to 85þ 12WB/Irish 6 Higher Managerial & Professionals
1 Intermediate
3 Technical & Craft
2 Not disclosed
Retirement Complex
3 groups (RFG1 -3)
15 14F
1M
65 to 85þ 15WB/Irish 9 Higher Managerial & Professionals
3 Intermediate
3 Technical & Craft
Sleep Apnoea Patients
3 groups (SAFG1 -3)
13 8M
5F
45–74 13WB/Irish 10 Higher Managerial & Professionals
1 Intermediate
2 Technical & Craft
Students


























52 Higher Managerial & Professionals
14 Intermediate Occupations





Vignettes Key themes picked out for discussion
1. Tom was referred to a specialist sleep clinic where he was diagnosed with narcolepsy. His doc-
tor has prescribed him modafinil to help him stay awake and feel more alert during
the daytime
Medical use of modafinil
2. Connie is 74 and lives in a residential care home. Her doctor has prescribed her sleeping pills
to help her sleep through the night. She also takes wake-promoting pills her daughter bought
for her on the Internet to boost her levels of daytime alertness and cognitive functioning
Non-prescription use of modafinil, older population
3. Jen is a student. She uses modafinil and finds that she is able to stay awake longer and con-
centrate better on her work when she takes the pills
Using modafinil to study
4. Nina is a palliative care nurse. Sometimes she uses sleeping pills to help her sleep in the day-
time. If she is struggling to stay awake at work she occasionally takes wake-promoting pills to
boost her levels of alertness
Workplace use of sleep and alertness drugs; safety
critical occupational context
5. Jamal works as a marketing director for a large multi-national company. He frequently uses
wake-promoting pills at the beginning of day and after international travel to improve his lev-
els alertness. He also finds that they help him to concentrate better, absorb information and
make important decisions more quickly
Workplace use of modafinil, knowledge worker
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conceptualised as a form of self- medication to ‘repair’ a per-
ceived problem of underperfomance and hence to ‘restore’
performance at ones best (Conrad & Potter, 2004).
Motivations for use were perceptions of underperformance
connected to a health or social problem that would lead to a
disadvantage if not remedied. Drug use in this imaginary was
depicted as an individualised practice.
Participants across several of the focus groups imagined
the use of PCEDs by people who might consider themselves
to be underperforming or operating below their own optimal
level, due to medical disorders (e.g. sleep disorders, allergies,
cancer, dementia) or other lifestyle factors (e.g. stress, pres-
sure, heavy workload, sleep deprivation, use of other sub-
stances that might impair cognition). Even though individuals
in these situations might have obtained pharmaceuticals out-
side of medical authority with the explicit goal of improving
their performance, PCED use in this type of scenario was gen-
erally regarded as a type of ‘self-medication’. See for
example, how the participants in an ambulance service focus
group discuss the use of modafinil by students in an exam
situation, reproducing, yet also recrafting a dominant
enhancement imaginary of PCED use:
Male 2: When you’ve got people that may have something like
hay fever and constantly feel as if they’ve got a cold and they
took something like that, then we would probably say that was
ok for them to do that.
Female 1: That’s true because it’s not like… you’ve still got to
have the knowledge to be able to recall, haven’t you, it’s not like
it’s going to… take the pill and you’re going to be able to solve
complex equations. It’s not going to give you an extra skill, is it?
Male 2: Anyone that’s had hay fever feels quite grotty and not at
their best.
Moderator: So, it’s for getting them up to their best?
Male 2: I suppose it’s getting them back up to best as opposed to
exceeding it which would be perceived as cheating in some ways.
(Ambulance Service Focus group 1)
The use of PCEDs was imagined as having a broadly thera-
peutic goal, despite being potentially procured outside of a
medical encounter. When PCEDs were configured as being
medicine – like, motivations for use were imagined as a way
to regain a normal or typical level of functioning (for that
individual) and to enable the user to ‘reach their potential’,
rather than ‘enhance’ cognitive capabilities beyond a previ-
ously attained level. Typically, this was viewed by our
respondents as being a socially acceptable goal and a mor-
ally acceptable practice.
Participants questioned why those who consider them-
selves to be high achievers would want to take a pill to try
and enhance their cognition if they were already functioning
well or performing at a high level. When PCEDs were consid-
ered to be medicine–like, the idea of taking drugs to become
‘better than well’ did not seem to make much sense. In the
data extract below, a medical student gives his view that
medication is usually used in order to remedy a perceived
problem or inadequacy:
Male 2: Most people who [study] medicine are actually quite
driven [… ] most people are Type A personality in my opinion so
most of the time you don’t need anything to motivate yourself
anymore [… ] I would much rather drink alcohol than I would
take anything that’s going to improve my performance because
I don’t struggle with learning stuff. It’s switching off which is the
thing. I think you medicate the thing you’re not so good at,
potentially, which is the whole point of drugs, isn’t it? (Student
Focus Group 3)
To summarise, when PCED use was positioned as a form
of ‘self-medication practice’, users were imagined as those
who perceived themselves to be performing at a sub-optimal
level, rather than people seeking to enhance performance
beyond the norm. In these imaginaries we can see how drug
use is made sense of as a means of remedying a perceived
problem or inadequacy, with PCED use a way for individuals
to become the best version of themselves. They are thus
positioning the ‘pharmaceuticalisation of performance’ (Lopes
et al., 2015) via PCEDs as an acute, short-term fix that would
be unnecessary or redundant for those who were already
able to perform at an adequate level, or with easy access to
other substances and strategies for improving particular
aspects of cognition (e.g. alertness).
This type of ‘enhancement practice’, although generally
viewed as being a morally acceptable use of PCEDs, jars with
current regulatory approaches to prospective PCEDs (e.g.
modafinil) that prohibit use of these drugs outside of very
specific clinically defined medical conditions. It also sits out-
side of the social imaginaries invoked in policy and ethical
debates where enhancement drug use tends to be imagined
as a way to improve performance beyond the norm, with
those who are using drugs afforded cognitive gains that put
them at advantage over others.
‘Pharmaceutical enablers’ to gain a competitive edge
over others
Reproducing aspects of dominant social imaginaries around
enhancement practices that circulate in research, policy and
media, our participants talked about PCED use as a means to
gain a competitive edge over others. PCEDs were typically
configured here not so much as pharmaceutical fixes for
underperformance but as ‘pharmaceutical enablers’ where
motivations for the use were to enhance performance in
order to gain a competitive edge over others. They imagined
this being likely to occur primarily in two social contexts; the
university and the workplace. Drug use in this imaginary was
discussed as a social practice, having effects on and implica-
tions for others beyond the user.
Participants imagined the type of student who would turn
to PCEDs in order to improve their performance; this was
often the young, typically male student who would take any-
thing on a short-term basis to ‘power through’ exams and
revision without having adequate rest. This imaginary is illus-
trated in the extract from a student focus group. The moral
consensus achieved through their discussion is clear:
Female 2: My observations of undergraduate men, there’s a sort
of macho mode of masculinities going on which is like yeah,
we’re just going to power on through and take these you know
[… ].you see it in the library, a very public drinking of these
energy drinks and the caffeine pill packets, [… ] And I can’t be
bothered with that really, I find that annoying [taking study drugs
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is] probably a bit of a false economy, if you’ve got any more than
one or two days to go on they’re going to feel dreadful so I kind
of think that it’s a bit silly and an immature approach to studying.
Moderator: So what would you think about people that did use
drugs to help them study?
Female 1: {… ) If it enhances performance I think that for me is
problematic.
Female 2: Like sports enhancement, like taking… like cheating.
Female 3: Just like cheating.
Female 1: That is like cheating, yeah. (Student Focus Group 1)
There are very few real life situations where cognitive per-
formance is quantified or measured. However, in one sense,
academic performance can be seen as an exception here.
Participants across all of our focus groups argued that if you
could demonstrate that academic performance was being
measurably improved in assessments by taking PCEDs, then
use of the pharmaceutical in this context would give an
unfair advantage to the user and could be considered
as cheating.
In terms of taking enhancement drugs in the workplace, a
particular type of worker was often imagined as a prospect-
ive user of PCEDs – a cognitive sector knowledge worker in a
high pressured and competitive environment, whose job and
performance at work was important to them, who needed to
‘be on the ball’ to perform and to make money. These peo-
ple, it was assumed, want more out of life but are willing to
put less in, and are willing to take short-cuts. The practice of
PCE in this context was considered vain, selfish, greedy and
taking the easy way out. As can be seen in the data extract
taken from a sleep apnoea focus group, the Hollywood film
‘Limitless’ served as a convenient cultural script within which
to articulate these ideas:
Male 2: The film Limitless, it’s about this enhancing drug, but the
guy keeps taking it because he suddenly realises that he can get
on better at work and when he doesn’t take it he doesn’t do so
well. And that’s a similar sort of thing here. Where’s the impetus
to stop if actually your day-to-day living becomes better because
of it?
Male 1: Well it’s interesting you say better there, because I think
one of the problems of modern life is that [… ] we have to
perform better all the time, instead of being able to actually work
at a reasonable rate [… ] I don’t think your happiness ought to
necessarily depend entirely on your work. And in a sense you
work in order to have happiness with your friends and your
family and so on. I’ve always felt that. (Sleep Apnoea Patients
Focus Group 3)
Despite reproducing elements of dominant social imaginaries
around enhancement in their discussions, participants did
not accept these ideas uncritically. They often discussed
which aspects of taking a PCED might actually be ‘enhancing’
across different social and occupational contexts. Thinking
beyond the student or knowledge worker, the limits to cog-
nitive enhancement were highlighted in terms of how
important these ‘enhanced’ functions might be for perform-
ance/output in different social or occupational roles.
However, it was easy for participants to imagine a wider
group of workers turning to enhancement drugs in the mod-
ern world. They discussed societal pressures such as heavy
workloads, balancing work and family life, stress and increas-
ingly competitive work environments where people are put
under pressure to succeed and to constantly perform better.
A small number of the participants thought that enhance-
ment drugs might be attractive to them and others like them
in this respect, particularly in certain occupations where the
search for a competitive edge is embedded in occupational
culture (e.g. barristers, stock brokers). However, this type of
PCED use was typically viewed as being morally dubious and
there was a strong collective belief that it would be wrong
for people to use PCEDs in order to seek an advantage over
others. Participants expressed discomfort at the idea that
people might feel they had to take PCEDs in order to per-
form at work – either to get ahead of others or just to
keep up.
The idea that performance whilst under the influence of
PCEDs would be both inauthentic and unappealing was often
expressed. This can be seen in the exchange below in a
Narcolepsy focus group:
Male 2: [… ] If you have got two guys going for a job and one of
them decides he is going to take modafinil or whatever while the
other guy doesn’t, the guy who’s taken the Modafinil could
potentially be sharper at interview or whatever but when it
comes down to the crux and he gets into the job and he’s not
taking Modafinil now he has falsely represented what he is and
what he is going to be and he will not achieve or maintain that
optimum that he demonstrated at interview.
Female 1: [… ] I don’t try and make my body do more than what
it can do because there are people who will just push and for me
that’s a kind of really nasty idea so I feel really happy to be with
what I am, just with what I am now. So I wouldn’t do any of this
extra hours or anything like that, not with the help of medication.
It just doesn’t appeal. (Narcolepsy Patients, Focus group 2)
Doubts were frequently expressed regarding the power of a
pill to provide this competitive edge and concerns raised
regarding possible health and social impacts of this sort of
drug use. Visions of a future society in which PCED use was
prolific, resulting in more pressure and higher expectations
of what people can realistically achieve were expressed.
These were used to frame concerns about the possible health
impacts of pushing oneself too hard and of social addiction,
in relation to the ability for users to stop taking PCEDs when
workplace pressures are unrelenting. Thus, within this imagin-
ary of enhancement drug use, prohibitive drug policy that
limits the availability of PCEDs in wider society was regarded
as way to protect workers from coercion, exploitation and
possible harms to health.
‘Creative tools’ for personal achievement or wellbeing
In contrast to imagining the use of PCEDs as a means to gain
a competitive edge over others, and in contract to the use of
PCEDs where there is a perceived deficit or problem the drug
is seen to be remedying, participants here drew on an
enhancement imaginary where PCEDs could be used as a
mean to boost productivity or cognitive performance in non-
competitive situations. Here, PCEDs take the role of ‘creative
tools’ that individuals can use to augment and modify them-
selves, as part of their private ‘body projects’ where there is
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no perceived issue or problem with current functioning. The
drug in this sense, in contrast to these previous two imag-
ined uses, is not treating anything but becomes instead an
individual, creative and experimental practice to alter bodies/
minds/performance for individual reasons, goals, aspirations.
Typically, self-modification and personal achievement was
regarded as being a socially acceptable motivation for seek-
ing out the use of enhancement drugs within a generally lib-
eral and individualistic frame. Understood in this way,
participants imagined how PCEDs could have a range of dif-
ferent effects on their users meaning that ‘enhancement’
would manifest in different ways:
Male 1: [Enhancement drug use is] actually using whatever to
take somebody to do their absolute best that they possibly can,
which you could argue, ‘is that actually a bad thing?’ because we
could, potentially, have lots of really fantastic people with lots of
different things.
Male 2: But, taking that to an extreme we would all be [athlete’s
name] then so we would all be doing exactly the same time?
Male 1: No, because you’ve all got your own abilities, haven’t you,
so it’s taking your personal ability to the [best it can possibly be].
(Ambulance service focus group 1)
As expressed in an academic focus group, the cognitive
enhancing effects of the drug would be qualitatively mean-
ingful in different ways across individual contexts. However,
at the same time, participants questioned the utility of taking
PCEDs to achieve a better quality of work. This can be seen
in the quote below where the participant frames potential
PCED use in an academic context in terms of individual
achievement in completing an academic project, while
expressing his doubts over whether the quality of academic
work would actually be improved by pharmaceutically aug-
menting cognition:
Male 1: I don’t take it. I don’t know anyone who does take it.
[… ] I can see the analogy with sport, but I kind of think of the
academic enterprise not as a competition [… ] if some people
use cognitive enhancing drugs in order to get a book written and
that gets published, I think of it not as something which stops
me from getting a book written and published without cognitive
enhancing drugs. And I’m not entirely sure whether a book
written under cognitive enhancing drugs would necessarily be
any better [… ] it might well be that this book is written in
record time, but it maybe has a narrative briskness that maybe
doesn’t suit the subject. [… ] So to that extent, I don’t quite see
it as the same as, say, you know, eight people on a track about
to run the 100 metres. (Academic Focus Group 1)
It was frequently stated that academic work is not always
about ‘remembering the right answers’ but instead about
building thoughtful, considered and reasoned arguments.
Working slowly and steadily over time was thought more
beneficial than taking a drug to improve memory or concen-
tration on a short-term basis. Overall, a high degree of scepti-
cism was expressed across the data set that taking PCEDs
would actually ‘enhance’ cognitive abilities in a way that
translated to enabling a higher quality of work.
Imagining PCED use as an individual and creative practice
enabled both the potential gains and losses associated with
drug use to be evaluated by prospective users for both the
individual and for wider society. In one sense, this
enhancement imaginary fits with the Transhumanist agenda
– in that people should have the freedom to use technology
to improve and enhance cognition, emotion, aesthetics and
abilities, engaging in their individual ‘body projects’ in any
way they chose. However, imagining PCED use in this way
enabled participants to consider what effects these drugs
might have in real world situations, how effects of the drug
would likely vary between individuals and context of use and
to question how meaningful or beneficial PCEDs would be
across each of these contexts.
‘Tools’ for personal and/or public safety
Lastly we turn to an enhancement imaginary where PCEDs
are configured as a type of ‘safety tool’ or technology. This
was a lesser theme in the data, but still worthy of note due
to its divergence from the other imagined enhancement
imaginaries discussed above. Participants imagined people
working in particular occupational roles that might benefit
from using PCEDs in order to keep them and others around
them safe. Military personnel, nurses, doctors, pilots and truck
drivers were all discussed in this vein in a retired persons
focus group.
Male 1: I think it’s a health and safety issue. I can take an extreme
case, for someone in a combat zone, in the armed forces, they
may need modafinil because they’re carrying out a life
threatening, gruelling, prolonged assignment. [… ] if it’s life
threatening, use it. (Retired persons, focus group 3)
When configuring PCEDs as ‘safety tools’, imagined drug use
could be conceptualised as having social value in enabling
those in safety critical occupations to perform safely, to help
others and do ‘positive work’ for the benefit of others, as
expressed in a narcolepsy focus group:
Moderator: You mentioned nursing where you felt that [modafinil
use] was legitimate, why did you feel that?
Female 1: I don’t know. Well it’s just a more worthy sort of thing
than a marketing director. She is doing positive work… for
other people…
Female 2: It is not necessarily a choice to do shift work because
obviously [… ] hospitals don’t shut so they have to have people
working these shifts all the time to take care of people and like
you are saying it is a more worthy cause, possibly but I’m not
sure. She’s doing good stuff. (Narcolepsy focus group 2)
Despite this, the ambulance service staff that participated in
our study did not view these issues as applicable to their
own work experience, where one may perhaps have expected
it on safety critical grounds. Typically, PCED use was regarded
as unnecessary in their occupational role as they were
already able to manage the effects of cognitive decline and
sleep deprivation in other ways. Moreover, as discussed in
relation to the more individualistic enhancement practices
outlined above, the effects of drug use on the health and
wellbeing of an individual was raised as a concern.
Participants discussed the potential side effects of drug use
in these contexts, particularly in terms of fostering depend-
ency and other possible effects on the body. Additionally,
they considered how the effects of the drug might impact
not only on the individual’s cognitive performance, but also
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on their ability to do their job and the quality of their work.
As a case in point, when talking about the possibility of a
nurse taking modafinil while working a night shift, partici-
pants in one academic focus group discussed the impacts
that improved cognitive function might have on empathy or
intuition. They recognised the possible benefits of improving
alertness and concentration but argued that it takes more
than this to be a good ‘human nurse’. Thus, participants
questioned the social value of improving certain aspects of
cognitive performance and discussed whether potential cog-
nitive enhancing effects of the drug (e.g. improving alert
wakefulness) would necessarily translate into them being
able to do their job better:
Male 2: The other thing is about how we’re characterizing the
nature of people who work there—we’re assuming that it’s a
cognitive activity that you have to be wakeful for, but is it a
purely cognitive activity? What effect does this drug have on the
things like empathy and intuition? So it may, if you characterise
the work in a purely productive, measurable way, look as if it’s
addressing risks, addressing concerns about safety, but I think we
need more information about the drug to really understand its
full effect. And also more information on the nature of work and
this particular form of work to understand whether it’s a good or
bad thing and whether it enhances safety, enhances quality as
well. It’s not just about safety. You basically want somebody
who’s safe but you also want somebody who’s good, a good and
human nurse. Or safe and human nurse. (Academic Focus
group 1)
Although the core aspect of this enhancement imaginary could
be seen as instrumental (e.g. taking a drug to improve one’s
memory or alertness level), participants tended to evaluate the
potential effects of this type of drug use in wider social and
relational terms. Imagining PCEDs as a type of safety tool
through which users seek ‘customisation’ (Williams, Coveney, &
Gabe, 2013) of their cognitive abilities and functioning allowed
drug use to be evaluated in terms of potential impacts on both
the individual, their health and functioning and on others.
Discussion
Most research on pharmaceutical cognitive enhancement to
date has focussed on the perceptions and practices of students
or young adults, to the relative exclusion of other social groups.
Our aim in this paper was to gain a better understanding of the
social imaginaries around pharmaceutical cognitive enhance-
ment, particularly around how people collectively imagine that
PCEDs might be used by themselves and others like them, how
motivations to engage or abstain from PCED use are imagined
and shared understandings of the desirability and acceptability
of these uses across multiple social contexts and groups.
As with any technological development, enhancement
drugs can be ‘flexibly interpreted’ or understood and used in
different ways by users in local contexts (Coveney, 2011). Our
data illustrate how PCED use is not understood as simply a
case of using pharmaceuticals as therapy (to treat illness) or
enhancement (to reach otherwise unobtainable levels of per-
formance or functioning). A range of ‘enhancement practices’
can be imagined and potentially enacted across different
social and occupational contexts. Far from having ‘stabilised’,
moreover, these social imaginaries are themselves overlap-
ping, with their own complexities and inconsistencies.
Participants frequently identified grey areas in which they
questioned whether the use of drugs to improve perform-
ance could be considered as ‘enhancement’ or not, despite
being obtained outside of clinical or medical advice and used
to improve performance, in particular when taking cognitive
enhancing drugs was conceptualised as a form of ‘self-medi-
cation’. In this case, pharmaceutical use was not perceived as
being motivated by an aspiration by the user to boost cogni-
tion above normal levels, and although being accessed and
used outside of it clinical indications, this type of use was still
considered to be therapeutic in many ways. The idea that
pharmaceuticals may be used outside of the clinical domain
as a means of self-medication is well-established in the exist-
ing literature around pharmaceutical cognitive enhancement
(Coveney, 2011; Lopes et al., 2015). Such self-medication ties
into contemporary bio-political ideas about health regarding
increasing individualisation, self-management and self-regula-
tion of body and performance in present-day societies (Rose,
2009). For this ‘enhancement practice’, optimisation (of one
aspect of the self) might be a more applicable term that bet-
ter describes perceived motivations for PCED use (Rose,
2009) where the pharmaceuticals in question are understood
and positioned more as ‘pharmaceutical fixes’ for a (self-
defined) problem rather than ‘enhancers’ (Martin et al., 2011)
Imagining PCED use as a way to improve performance in
order to gain a competitive edge over others is one of the
dominant social imaginaries circulating in academic, policy,
regulatory and media discourses about pharmaceutical
enhancement. Within this enhancement imaginary PCED use
is typically framed as a form of prescription drug ‘misuse or
abuse’ (Racine & Forlini, 2010). It shapes understandings of
PCED in a particular way by focussing on cultural ideas of
competition, fairness, productivity and ‘authenticity’, of drug
abuse and harms to health. Thus, arguments for tight regula-
tory controls and the adoption of prohibitive drug policies
tend to follow on from this as means to protect prospective
users from exploitation or harm. Likewise, this type of
enhancement practice was readily imagined during our focus
group discussions. However, in our data, in this enhancement
imaginary, drug use was positioned as an individual solution
to a structural problem; with pharmaceuticals acting as
‘enablers’ as much as ‘enhancers’ in that they were regarded
as functioning to enable individuals to continue to partici-
pate and perform in competitive environments where expect-
ations exist for people to continually perform at a high level
and constantly strive to do better. In this sense, PCEDs were
regarded as a tool of modernity – a way to keep going and
do more. Frequently, similarities were drawn between PCED
use and existing ‘performance consumptions’ (Lopes et al.,
2015) such as using caffeine and energy drinks as aids to
promoting alertness, concentration and wakefulness.
Alternative enhancement practices were also imagined in
which motivations for engaging in drug use were for per-
sonal achievement or to mitigate against safety risks. PCEDs
were positioned as ‘tools’ at our disposal which we can use
at an individual level to aid creativity or in a collective or
relational context, as good citizens promoting workplace
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safety. Underpinning both of these imaginaries was the idea
that the qualitative effects of PCEDs would be variable
between individuals and between contexts. Throughout,
there was a high level of scepticism that a PCED would
deliver meaningful effects, and provides substantial gains
without losses.
One of the key themes that cuts across each of the
enhancement practice we discuss above was that the way in
which people understand and define ‘enhancement’ is highly
subjective. In addition, what people might seek to ‘enhance’
by taking PCEDs differs between individuals and between
contexts. There was a strong sense across the data that
everyone has different abilities, strengths and weaknesses so
taking enhancement drugs will reflect that. In taking these
drugs, we would see a variation of effects between users.
Also, this was the case in regard to the relative importance
of what particular function or capacity was actually being
improved or enhanced through drug use in relation to other
aspects of the self. This finding bears similarity to other
research on cognitive enhancement, which points to the sig-
nificance of emotion and the effects of drug use on feelings
of wellbeing, pleasure and enjoyment in enhancement practi-
ces (e.g. Petersen et al., 2015; Vrecko, 2013), signifying that
there is an overemphasis on cognition in dominant bioethical
and policy accounts of drug use of this type (Ketchum, 2013).
Context of use, imagined motivations for use and current
drug policy all influence moral judgements around pharmaceut-
ical use. Not all ‘enhancement’ practices were perceived to be
morally equivalent. Respondents differentiated between using
drugs to achieve ones best, for personal achievement or to
help others (which were viewed as socially acceptable goals)
with their use to get ahead, to gain an advantage over others
in directly competitive situations or to make money (in ethically
dubious ways). The perceived motivations for enhancement, in
addition to the context in which pharmaceutical enhancements
might be used, and who the users were imagined to be were
important factors in judging the social/moral acceptability of
pharmaceutical cognitive enhancement. In addition, the regula-
tory context within which PCEDs are obtained influences per-
ceptions of safety and ‘proper use’ (Coveney, 2011).
We can see how enhancement is a ‘slippery’ term that can
have multiple meanings. In turn, PCEDs can become slippery
objects in policy debates, with different ways to conceptual-
ise them, how they are being used and why. Thus, our data
further questions the distinctions that one might make
between medical and non-medical use of PCEDs and sup-
ports the idea that the TED does not capture the range of
drug use, user motivations or experiences and therefore can-
not perform the role expected of it in policy making; that is
to say what is worthy, acceptable, or justifiable in terms of
resource allocation (Coveney, 2011; Erler, 2017)
To summarise, we problematise the term ‘enhancement’
by showing the different ways in which it can be understood
and what it means to people in the context of their daily
lives. Further, we problematise assumed motivations for seek-
ing enhancement in regard to these imagined enhancement
practices. Using PCEDs is not all about enhancing cognition
beyond the norm and not all non-clinical use is perceived to
be non-therapeutic.
We argue for conceptualisation of PCE as multiple
‘enhancement practices’, that are at once material, embodied
and discursive in nature, and are entangled with various imagi-
naries of the user and their motivations, desires, goals, aspira-
tions, ambitions and expectations. Pharmaceuticals can be
viewed as actors in these assemblages, taking on various roles
as fixers, helpers, enablers, enhancers, creative and safety tools.
Based on our data, we might also pause to reflect on whether
calling these imagined uses of pharmaceuticals ‘enhancement’
practices is the most appropriate terminology to describe how
people think about the many possible uses of such drugs out-
side of their use as prescription medicines for treating medic-
ally sanctioned clinical indications.
Implications for policy
How people think about and evaluate new technologies in the
context of their daily lives is important for future policy. There
is a need ‘to understand the situations, pressures, and expecta-
tions that lead users to seek performance enhancement’
(Ketchum, 2013:27) in order to understand how and why these
drugs might come to be used, accepted, resisted or rejected
across society and in and between different social groups.
The urgency of a new policy or regulatory response to
PCED use is not clear. Evidence suggests that regulatory
changes are not imperative; use is not particularly wide-
spread at a population level in the UK and the enhancers
currently available are not considered to be particularly
effective (Ragan et al., 2013). However, considering that in
the UK at least, a drug free/abstinent society is the dominant
political, social and cultural imaginary, current regulatory
approaches do not appear to be inhibiting the use of
pharmaceutical cognitive enhancers as studies continually
show that there is a small (albeit significant and growing)
market for these substances.
Based on our findings we suggest that nuanced under-
standings of PCED use are emerging in particular social and
cultural niches. Future drug policy and regulatory reviews
could incorporate insights from wider ‘enhancement imagina-
ries’ to better reflect prospective uses across a broader range
of contexts than those currently being imagined in policy
debates. An integrative strategy that recognises the enhance-
ment practices that prospective users envisage themselves
and others like them engaging in may contribute towards
more accurate assessments of the social implications of the
proliferation of PCEDs and help in the development of better
informed regulatory approaches. Returning to the wider pol-
icy debates on human enhancement discussed earlier – and
without taking any normative stance on these matters our-
selves – perhaps they might also consider the merits not sim-
ply of precauationary but proactionary (Lipinska & Fuller,
2014) approaches to these matters in the interests of more
nuanced future policy responses which balance individual
freedoms with collective and democratic issues of social just-
ice and social welfare.
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